Nirvana Life Sciences Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NIRV.CN research report →
Companynirvanalifesciences.com
Nirvana Life Sciences Inc. engages in the scientific research and development of therapeutic products derived from psychedelics. It also focuses on developing methodologies for extraction and purification of psychoactive compounds; and the improvement of propagation techniques for growing such biomass on a large scale.
- CEO
- Bruce Clark
- IPO
- 2022
- HQ
- Vancouver, BC, CA
Price Chart
Valuation
- Market Cap
- $337.63K
- P/E
- -5.60
- P/S
- 0.00
- P/B
- -3.06
- EV/EBITDA
- -1.78
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 25.70%
- ROIC
- 65.97%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-365,918 · 0.00%
- EPS
- $-0.08 · 0.00%
- Op Income
- $-339,944
- FCF YoY
- 0.00%
Performance & Tape
- 52W High
- $0.50
- 52W Low
- $0.03
- 50D MA
- $0.07
- 200D MA
- $0.08
- Beta
- -0.06
- Avg Volume
- 1.31K
Get TickerSpark's AI analysis on NIRV.CN
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our NIRV.CN Coverage
We haven't published any research on NIRV.CN yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate NIRV.CN Report →